Despite their well‐known survival benefits in HF patients, there is no clear guidance on the use of beta‐blockers, angiotensin‐converting enzyme inhibitors (ACEis), angiotensin‐receptor blockers (ARBs) and mineralo‐corticoid receptor antagonists (MRAs) in CKD–HF patients due to exclusion of severe CKD patients from major clinical trials.1 This evidence concerns the gene NR3C2 and chronic kidney disease.